Incentivizing appropriate malaria case management in the private sector: a study protocol for two linked cluster randomized controlled trials to evaluate provider- and client-focused interventions in western Kenya and Lagos, Nigeria

Aaron M Woolsey, Ryan A Simmons, Meley Woldeghebriel, Yunji Zhou, Oluwatosin Ogunsola, Sarah Laing, Tayo Olaleye, Joseph Kipkoech, Bomar Mendez Rojas, Indrani Saran, Mercy Odhiambo, Josephine Malinga, George Ambani, Emmah Kimachas, Chizoba Fashanu, Owens Wiwa, Diana Menya, Jeremiah Laktabai, Theodoor Visser, Elizabeth L Turner, Wendy Prudhomme O'Meara, Aaron M Woolsey, Ryan A Simmons, Meley Woldeghebriel, Yunji Zhou, Oluwatosin Ogunsola, Sarah Laing, Tayo Olaleye, Joseph Kipkoech, Bomar Mendez Rojas, Indrani Saran, Mercy Odhiambo, Josephine Malinga, George Ambani, Emmah Kimachas, Chizoba Fashanu, Owens Wiwa, Diana Menya, Jeremiah Laktabai, Theodoor Visser, Elizabeth L Turner, Wendy Prudhomme O'Meara

Abstract

Background: A large proportion of artemisinin-combination therapy (ACT) anti-malarial medicines is consumed by individuals that do not have malaria. The over-consumption of ACTs is largely driven by retail sales in high malaria-endemic countries to clients who have not received a confirmatory diagnosis. This study aims to target ACT sales to clients receiving a confirmatory diagnosis using malaria rapid diagnostic tests (mRDTs) at retail outlets in Kenya and Nigeria.

Methods: This study comprises two linked four-arm 2 × 2 factorial cluster randomized controlled trials focused on malaria diagnostic testing and conditional ACT subsidies with the goal to evaluate provider-directed and client-directed interventions. The linked trials will be conducted at two contrasting study sites: a rural region around Webuye in western Kenya and the urban center of Lagos, Nigeria. Clusters are 41 and 48 participating retail outlets in Kenya and Nigeria, respectively. Clients seeking care at participating outlets across all arms will be given the option of paying for a mRDT-at a study-recommended price-to be conducted at the outlet. In the provider-directed intervention arm, the outlet owner receives a small monetary incentive to perform the mRDT. In the client-directed intervention arm, the client receives a free ACT if they purchase an mRDT and receive a positive test result. Finally, the fourth study arm combines both the provider- and client-directed interventions. The diagnosis and treatment choices made during each transaction will be captured using a mobile phone app. Study outcomes will be collected through exit interviews with clients, who sought care for febrile illness, at each of the enrolled retail outlets.

Results: The primary outcome measure is the proportion of all ACTs that are sold to malaria test-positive clients in each study arm. For all secondary outcomes, we will evaluate the degree to which the interventions affect purchasing behavior among people seeking care for a febrile illness at the retail outlet.

Conclusions: If our study demonstrates that malaria case management can be improved in the retail sector, it could reduce overconsumption of ACTs and enhance targeting of publicly funded treatment reimbursements, lowering the economic barrier to appropriate diagnosis and treatment for patients with malaria.

Trial registration: ClinicalTrials.gov NCT04428307 , registered June 9, 2020, and NCT04428385 , registered June 9, 2020.

Keywords: ACT; Malaria; Private sector; RDT; Subsidies; Subsidy.

Conflict of interest statement

The authors declare that they have no competing or conflicting interests.

Figures

Fig. 1
Fig. 1
Study settings in western Kenya and Lagos, Nigeria. Shaded areas indicate the areas where the TESTsmART study will be conducted, and the number of clusters in a Nigeria and b Kenya
Fig. 2
Fig. 2
Decision tree of client diagnosis and treatment data collected through exit interviews and by the TESTsmART mobile app
Fig. 3
Fig. 3
Selection of retail outlets for enrollment in the TESTsmART study

References

    1. WHO, editor. Guidelines for the treatment of malaria. 2nd ed: WHO; 2010.
    1. Cohen JM, Woolsey AM, Sabot OJ, Gething PW, Tatem AJ, Moonen B. American Association for the Advancement of Science. 2012. Optimizing investments in malaria treatment and diagnosis. Vol. 338, science; pp. 612–614.
    1. World malaria report 2019. [cited 2020 Nov 11]. Available from: .
    1. Opiyo N, Yamey G, Garner P. Subsidising artemisinin-based combination therapy in the private retail sector. Vol. 2016, Cochrane database of systematic reviews: Wiley; 2016.
    1. Nwokolo E, Ujuju C, Anyanti J, Isiguzo C, Udoye I, Bongos-Ikwue E, et al. Misuse of artemisinin combination therapies by clients of medicine retailers suspected to have malaria without prior parasitological confirmation in Nigeria. Int J Health Policy Manag. 2018;7(6):542–548. doi: 10.15171/ijhpm.2017.122.
    1. Mbonye AK, Lal S, Cundill B, Hansen KS, Clarke S, Magnussen P. Treatment of fevers prior to introducing rapid diagnostic tests for malaria in registered drug shops in Uganda. Malar J. 2013;12(1):1–10. doi: 10.1186/1475-2875-12-1.
    1. Briggs MA, Kalolella A, Bruxvoort K, Wiegand R, Lopez G, Festo C, et al. Prevalence of malaria parasitemia and purchase of artemisinin-based combination therapies (ACTs) among drug shop clients in two regions in Tanzania with ACT subsidies. Eisele T, editor. PLoS One. 2014;9(4):e94074. doi: 10.1371/journal.pone.0094074.
    1. Prudhomme O’Meara W, Menya D, Laktabai J, Platt A, Saran I, Maffioli E, et al. Improving rational use of ACTs through diagnosis-dependent subsidies: evidence from a cluster-randomized controlled trial in western Kenya. von Seidlein L, editor. PLoS Med. 2018;15(7):e1002607. doi: 10.1371/journal.pmed.1002607.
    1. Laktabai J, Saran I, Zhou Y, Simmons RA, Turner EL, Visser T, et al. Subsidise the test, the treatment or both? Results of an individually randomised controlled trial of the management of suspected malaria fevers in the retail sector in western Kenya. BMJ Glob Health. 2020;5(11):e003378. doi: 10.1136/bmjgh-2020-003378.
    1. Hanson K, Goodman C. Testing times: trends in availability, price, and market share of malaria diagnostics in the public and private healthcare sector across eight sub-Saharan African countries from 2009 to 2015. Malar J. 2017;16(1):205. doi: 10.1186/s12936-017-1829-5.
    1. Musuva A, Ejersa W, Kiptui R, Memusi D, Abwao E. The malaria testing and treatment landscape in Kenya: results from a nationally representative survey among the public and private sector in 2016. Malar J. 2017;16(1):494. doi: 10.1186/s12936-017-2089-0.
    1. Hayes RJ, Moulton LH. Cluster randomised trials, second edition. 2017.
    1. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs holm methods. Am J Public Health. 1996.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform J Biomed Inf. 2009.
    1. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019.
    1. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004.
    1. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res. 2013.
    1. Zeger SL, Liang K-Y, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988.
    1. Preisser JS, Young ML, Zaccaro DJ, Wolfson M. An integrated population-averaged approach to the design, analysis and sample size determination of cluster-unit trials. Stat Med. 2003.
    1. Adeyi O, Atun R. Innovating for impact: the affordable medicines facility-malaria (AMFm). Nat Med. 2009.
    1. AMFm. Independent evaluation of phase 1 of the affordable medicines facility - malaria (AMFm), multi-country independent evaluation report: final report. Calverton Md Lond ICF Int Lond Sch Hyg Trop Med. 2012.

Source: PubMed

3
Subskrybuj